Health Care·Life Sciences Tools & Services·$32.7B
Agilent Technologies is a leading company in the health care sector, specializing in life sciences tools and services. Their products are essential for laboratories and researchers, helping to advance scientific discovery and improve patient outcomes.
EPS
Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
Total revenue reflects the company's sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
0Q
EPS Beat Rate
75%
Avg EPS Surprise
+1.94%
Avg Stock Reaction
+0.10%
In Q1-2026, Agilent reported an EPS of $1.36, slightly missing the estimate of $1.37. The stock reacted positively, gaining 0.26% the following day.
Management Promises & Guidance
Analysts expect Agilent to report an EPS of $1.41 and revenue of $1.8 billion for Q2-2026. The company has a history of beating earnings estimates, which could influence market sentiment.
Bull Case
If Agilent exceeds the EPS estimate, it could signal strong demand for its products and enhance investor confidence, potentially leading to a stock price increase.
Bear Case
Conversely, if Agilent misses the EPS target, it may raise concerns about its growth prospects and market competitiveness, leading to a negative reaction in the stock.
EPS
$1.41Earnings per share is a key indicator of the company's profitability and financial health.
Revenue
$1.8BTotal revenue reflects the company's sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will Agilent achieve an EPS of $1.41 or higher?
This figure is critical as it sets the tone for investor confidence and reflects the company's operational efficiency.
Q2
What insights can Agilent provide about revenue growth in its key segments?
Understanding revenue drivers will help investors gauge the company's market position and future growth potential.
Why consensus could be wrong
The consensus may underestimate Agilent's ability to leverage new product innovations, which could lead to stronger-than-expected revenue growth this quarter.
Supporting Evidence
Agilent has a track record of beating EPS estimates 75% of the time, suggesting potential for upside.
Recent trends in the life sciences sector indicate increased demand for advanced laboratory tools, which Agilent is well-positioned to capitalize on.
Key Risk
If Agilent's revenue growth exceeds $1.8 billion, it could challenge the current consensus view and drive the stock higher.
Pre-commit to what would confirm each case.
The market is closely watching Agilent's ability to meet or exceed earnings expectations, which will heavily influence stock performance.
Bull Confirmed If
An EPS of $1.42 or higher would confirm strong operational performance and market demand.
Bear Confirmed If
An EPS below $1.39 would raise concerns about the company's growth trajectory and market competitiveness.
Implied Move
±N/A
No options market data is available to gauge investor sentiment ahead of the earnings report.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If Agilent beats expectations, history suggests a modest positive reaction, potentially confirming strong demand and operational efficiency.
In-Line / Cautious
If results are in line with expectations, the market may react cautiously, focusing on management's commentary for future guidance.
Miss
A miss could lead to a negative reaction, with history suggesting a potential average decline of around 0.29%.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
GRUPO FINANCIERO GAL B ADR
May 26, 2026